Pure Global

EbraQik COVID-19 Rapid Antigen Test - India CDSCO Medical Device Registration

EbraQik COVID-19 Rapid Antigen Test is a medical device registered with India's Central Drugs Standard Control Organization (CDSCO) under UID MFG/IVD/2020/000014_a78e4b7b08890518c34050881b63862d_56ca4908dd1ad81fddffba3a108b1ed0. This device is marketed under the brand name ERBAQIK Dengue Alpha NS1Ag. The license holder is M/s.Transasia Bio-Medicals Ltd., and it is classified as Device Class Class C. The approving authority is Central Drug Standards Control Organization, West Zone.

This page provides comprehensive regulatory information including complete registration details, license holder information, device classification, and related products. Pure Global AI offers free access to 71,807+ India medical device registrations, helping global MedTech companies identify partners, analyze markets, and discover business opportunities efficiently.

Free Database
Powered by Pure Global AI
CDSCO Registered
Class Class C
EbraQik COVID-19 Rapid Antigen Test
UID: MFG/IVD/2020/000014_a78e4b7b08890518c34050881b63862d_56ca4908dd1ad81fddffba3a108b1ed0

Brand Name

ERBAQIK Dengue Alpha NS1Ag

Device Class

Class C

Approving Authority

Central Drug Standards Control Organization, West Zone

Product Information

ErbaQik COVID-19 Ag test is intended for self-testing at home for the detection of COVID-19 Antigen in human Nasopharyngeal Sample. This test is authorized and intended for non-prescription home use as self-test with the self-collected nasal specimens from individuals of age 18 years or older & with adult collected nasal specimen from individuals aged 2 years or older. The report is provided by ErbaQik App (ERBAQIK Dengue Alpha NS1Ag) and the results can be interpreted by the user

Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing